Drug intelligence / Profile preview

PRO-179

Development stage: Phase 4
Lead developer: Laboratorios Sophia
Modality: Small Molecules
Administration: Ophthalmic

Overview

PRO-179 is an ophthalmic solution developed by Sophia Laboratories S.A. de C.V. for the treatment of glaucoma. It contains the active ingredient travoprost, which is a small molecule prostaglandin analog. PRO-179 acts as a selective agonist at the prostaglandin F (FP) receptor, a mechanism that facilitates the reduction of intraocular pressure by increasing the uveoscleral outflow of aqueous humor. The drug has been evaluated in Phase 1 clinical trials (such as NCT03965052) to compare its safety, tolerability, and ocular surface profile against the reference brand-name product, Travatan.

Brand names: Travatan ZTravatan
Other names: travoprost ophthalmic solution

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on PRO-179.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRO-179.

Explore the full profile